Adverse events associated with escalating imatinib versus switching to dasatinib in patients with chronic myelegenous leukemia ...

“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...

A distinct signaling pathway called TNF-α drives the transformation of epithelial cells into aggressive tumor cells. During cancer progression, cells activate their own TNF-α program and become ...

Abrogation of tumor necrosis alpha (TNF-alpha) pathway by anti-TNF therapy in hematological malignancies This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting I. This abstract does not ...